Allogeneic double‐negative T cell therapy for relapsed <scp>acute myeloid leukemia</scp> patients post <scp>allogeneic hematopoietic stem cell transplantation</scp>: A first‐in‐human phase I studyBaolin Tang, Xiaoyu Zhu, Wen Yao et al.|American Journal of Hematology|2022Cited by 26
Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients after allo-HSCT: A phase I trial.Xiaoyu Zhu, Liming Yang, Guangyu Sun et al.|Journal of Clinical Oncology|2025Cited by 1